Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment
Standard
Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment. / Ashraf, Shazia; Kudo, Hiroki; Rao, Jia; Kikuchi, Atsuo; Widmeier, Eugen; Lawson, Jennifer A; Tan, Weizhen; Hermle, Tobias; Warejko, Jillian K; Shril, Shirlee; Airik, Merlin; Jobst-Schwan, Tilman; Lovric, Svjetlana; Braun, Daniela A; Gee, Heon Yung; Schapiro, David; Majmundar, Amar J; Sadowski, Carolin E; Pabst, Werner L; Daga, Ankana; van der Ven, Amelie T; Schmidt, Johanna M; Low, Boon Chuan; Gupta, Anjali Bansal; Tripathi, Brajendra K; Wong, Jenny; Campbell, Kirk; Metcalfe, Kay; Schanze, Denny; Niihori, Tetsuya; Kaito, Hiroshi; Nozu, Kandai; Tsukaguchi, Hiroyasu; Tanaka, Ryojiro; Hamahira, Kiyoshi; Kobayashi, Yasuko; Takizawa, Takumi; Funayama, Ryo; Nakayama, Keiko; Aoki, Yoko; Kumagai, Naonori; Iijima, Kazumoto; Fehrenbach, Henry; Kari, Jameela A; El Desoky, Sherif; Jalalah, Sawsan; Bogdanovic, Radovan; Stajić, Nataša; Zappel, Hildegard; Rakhmetova, Assel; Wassmer, Sharon-Rose; Jungraithmayr, Therese; Strehlau, Juergen; Kumar, Aravind Selvin; Bagga, Arvind; Soliman, Neveen A; Mane, Shrikant M; Kaufman, Lewis; Lowy, Douglas R; Jairajpuri, Mohamad A; Lifton, Richard P; Pei, York; Zenker, Martin; Kure, Shigeo; Hildebrandt, Friedhelm.
in: NAT COMMUN, Jahrgang 9, Nr. 1, 17.05.2018, S. 1960.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment
AU - Ashraf, Shazia
AU - Kudo, Hiroki
AU - Rao, Jia
AU - Kikuchi, Atsuo
AU - Widmeier, Eugen
AU - Lawson, Jennifer A
AU - Tan, Weizhen
AU - Hermle, Tobias
AU - Warejko, Jillian K
AU - Shril, Shirlee
AU - Airik, Merlin
AU - Jobst-Schwan, Tilman
AU - Lovric, Svjetlana
AU - Braun, Daniela A
AU - Gee, Heon Yung
AU - Schapiro, David
AU - Majmundar, Amar J
AU - Sadowski, Carolin E
AU - Pabst, Werner L
AU - Daga, Ankana
AU - van der Ven, Amelie T
AU - Schmidt, Johanna M
AU - Low, Boon Chuan
AU - Gupta, Anjali Bansal
AU - Tripathi, Brajendra K
AU - Wong, Jenny
AU - Campbell, Kirk
AU - Metcalfe, Kay
AU - Schanze, Denny
AU - Niihori, Tetsuya
AU - Kaito, Hiroshi
AU - Nozu, Kandai
AU - Tsukaguchi, Hiroyasu
AU - Tanaka, Ryojiro
AU - Hamahira, Kiyoshi
AU - Kobayashi, Yasuko
AU - Takizawa, Takumi
AU - Funayama, Ryo
AU - Nakayama, Keiko
AU - Aoki, Yoko
AU - Kumagai, Naonori
AU - Iijima, Kazumoto
AU - Fehrenbach, Henry
AU - Kari, Jameela A
AU - El Desoky, Sherif
AU - Jalalah, Sawsan
AU - Bogdanovic, Radovan
AU - Stajić, Nataša
AU - Zappel, Hildegard
AU - Rakhmetova, Assel
AU - Wassmer, Sharon-Rose
AU - Jungraithmayr, Therese
AU - Strehlau, Juergen
AU - Kumar, Aravind Selvin
AU - Bagga, Arvind
AU - Soliman, Neveen A
AU - Mane, Shrikant M
AU - Kaufman, Lewis
AU - Lowy, Douglas R
AU - Jairajpuri, Mohamad A
AU - Lifton, Richard P
AU - Pei, York
AU - Zenker, Martin
AU - Kure, Shigeo
AU - Hildebrandt, Friedhelm
PY - 2018/5/17
Y1 - 2018/5/17
N2 - No efficient treatment exists for nephrotic syndrome (NS), a frequent cause of chronic kidney disease. Here we show mutations in six different genes (MAGI2, TNS2, DLC1, CDK20, ITSN1, ITSN2) as causing NS in 17 families with partially treatment-sensitive NS (pTSNS). These proteins interact and we delineate their roles in Rho-like small GTPase (RLSG) activity, and demonstrate deficiency for mutants of pTSNS patients. We find that CDK20 regulates DLC1. Knockdown of MAGI2, DLC1, or CDK20 in cultured podocytes reduces migration rate. Treatment with dexamethasone abolishes RhoA activation by knockdown of DLC1 or CDK20 indicating that steroid treatment in patients with pTSNS and mutations in these genes is mediated by this RLSG module. Furthermore, we discover ITSN1 and ITSN2 as podocytic guanine nucleotide exchange factors for Cdc42. We generate Itsn2-L knockout mice that recapitulate the mild NS phenotype. We, thus, define a functional network of RhoA regulation, thereby revealing potential therapeutic targets.
AB - No efficient treatment exists for nephrotic syndrome (NS), a frequent cause of chronic kidney disease. Here we show mutations in six different genes (MAGI2, TNS2, DLC1, CDK20, ITSN1, ITSN2) as causing NS in 17 families with partially treatment-sensitive NS (pTSNS). These proteins interact and we delineate their roles in Rho-like small GTPase (RLSG) activity, and demonstrate deficiency for mutants of pTSNS patients. We find that CDK20 regulates DLC1. Knockdown of MAGI2, DLC1, or CDK20 in cultured podocytes reduces migration rate. Treatment with dexamethasone abolishes RhoA activation by knockdown of DLC1 or CDK20 indicating that steroid treatment in patients with pTSNS and mutations in these genes is mediated by this RLSG module. Furthermore, we discover ITSN1 and ITSN2 as podocytic guanine nucleotide exchange factors for Cdc42. We generate Itsn2-L knockout mice that recapitulate the mild NS phenotype. We, thus, define a functional network of RhoA regulation, thereby revealing potential therapeutic targets.
KW - Adult
KW - Animals
KW - Child
KW - Child, Preschool
KW - DNA Mutational Analysis
KW - Disease Models, Animal
KW - Drug Resistance/genetics
KW - Female
KW - Gene Knockdown Techniques
KW - Glucocorticoids/pharmacology
KW - HEK293 Cells
KW - High-Throughput Nucleotide Sequencing
KW - Humans
KW - Infant
KW - Male
KW - Mice
KW - Mice, Inbred C57BL
KW - Mice, Knockout
KW - Middle Aged
KW - Mutation
KW - Nephrotic Syndrome/drug therapy
KW - Pedigree
KW - Podocytes
KW - Protein Interaction Maps/genetics
KW - RNA, Small Interfering/metabolism
KW - Treatment Outcome
KW - Whole Exome Sequencing
KW - rhoA GTP-Binding Protein/genetics
U2 - 10.1038/s41467-018-04193-w
DO - 10.1038/s41467-018-04193-w
M3 - SCORING: Journal article
C2 - 29773874
VL - 9
SP - 1960
JO - NAT COMMUN
JF - NAT COMMUN
SN - 2041-1723
IS - 1
ER -